How is the Trevi Therapeutics Inc today?

The Trevi Therapeutics Inc today is trading in the down by -2.43% at 6.03.

What is Trevi Therapeutics Inc Annual Net Profit?

Trevi Therapeutics Inc Annual Net Profit fell 64.84% in the last year to $47.91 M. Its sector's average net profit growth for the last fiscal year was -11.13%.

What is Trevi Therapeutics Inc Price to Earning Ratio?

Trevi Therapeutics Inc Price to Earning Ratio is -12.96, which is negative.

What is Trevi Therapeutics Inc Stock Price?

Trevi Therapeutics Inc Stock Price rose 127.55% and outperformed its sector by 116.01% in the past year.

What is Trevi Therapeutics Inc Quarterly Net profit?

Trevi Therapeutics Inc Quarterly Net profit rose 5.16% YoY to $10.34 M. Its sector's average net profit growth YoY for the quarter was -212.2%.

What is Trevi Therapeutics Inc Debt to Equity Ratio?

Trevi Therapeutics Inc Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Trevi Therapeutics Inc Return on Equity(ROE)?

Trevi Therapeutics Inc Return on Equity(ROE) for the last financial year was -52.59%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Trevi Therapeutics Inc Mutual Fund Holding?

Trevi Therapeutics Inc Mutual Fund Holding increased by 2.18% in the last quarter to 17.4.

What is Trevi Therapeutics Inc Promoter Share Holding?

Trevi Therapeutics Inc Promoter Share Holding increased by 0.18% in the most recent quarter to 5.52%.

What is Trevi Therapeutics Inc Interest Coverage Ratio?

Trevi Therapeutics Inc Interest Coverage Ratio is -11984.25, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Trevi Therapeutics Inc Institutional Holding?

Trevi Therapeutics Inc Institutional Holding increased by 3.17% in the last quarter to 68.95.

Trevi Therapeutics Inc XNAS: TRVI

Trevi Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Trevi Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Trevi Therapeutics Inc
Rating: 1.79441675
Author: Trendlyne DVM scores

about

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary f...

6.03 -0.15 (-2.43%)

162.17% Gain from 52W Low

671.0K XNAS Volume

XNAS 22 May, 2025 5:30 PM (EDT)

Not Eligible

-

Expensive Valuation

3.2 / 100

Technically Moderately Bullish

68.6 / 100

No estimates available

Trevi Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Trevi Therapeutics Inc FAQ

How is Trevi Therapeutics Inc today?

Trevi Therapeutics Inc today is trading in the red, and is down by -2.43% at 6.03.

How has Trevi Therapeutics Inc performed historically?

Trevi Therapeutics Inc is currently trading down -2.43% on an intraday basis. In the past week the stock fell -2.58%. stock has been up 31.09% in the past quarter and rose 127.55% in the past year. You can view this in the overview section.